Beyond CAR-T Therapy: The Need for Long-Term Safety Validation

Led by the National Cancer Institute (NCI), a clinical trial (NCT05237986) has commenced to investigate the long-term neurotoxic cognitive sequelae in pediatric leukemia and lymphoma patients undergoing innovative chimeric antigen receptor T-cell (CAR T-cell) therapy. While CAR-T cell therapy is an immunotherapy that attacks cancer cells, it has a significant drawback: it causes immune-related neurotoxicity syndrome (ICANS) in 18% to 68% of patients. The industry, which has focused on managing acute adverse effects, now aims to identify the risks to the cognitive development of pediatric and adolescent patients with high survival rates. This is a strategic measure to protect the quality of life of patients by preventing permanent brain damage and extending survival.

Multi-faceted Clinical Design and Long-Term Monitoring System

This prospective cohort study will track 60 patients aged 5 to 35 years before CAR-T therapy for approximately three years. Using the Cogstate test, a computer-based cognitive assessment tool, along with caregiver-observed data, the study will analyze the rate of change in working memory at 12 months. A key objective of this clinical trial is to compare biomarkers at the time of ICANS onset with long-term cognitive decline. This precise investigation will provide the first scientific data to demonstrate subtle cognitive changes, such as learning disabilities or memory loss, in pediatric patients recovering after treatment.

Impact on Blockbuster CAR-T Market Led by Novartis and Gilead

Currently, the pediatric leukemia field is dominated by Kymriah (tisagenlecleucel) from Novartis and Yescarta (axicabtagene ciloleucel) from Gilead. Despite their excellent efficacy, these CD19-targeted therapies have been subject to strict Risk Evaluation and Mitigation Strategies (REMS) regulations at the time of FDA approval due to their high incidence of neurotoxicity. If the long-term sequelae of neurotoxicity are confirmed in this clinical trial, the prescription criteria for existing blockbuster drugs may become stricter. This will be a symbolic sign that regulatory agencies are beginning to apply more stringent standards to long-term safety profiles.

Prospects for a Generational Shift to Next-Generation Safety-Enhanced Platforms

The pharmaceutical and biotechnology industries are accelerating the development of next-generation CAR-T therapies with reduced toxicity. To suppress excessive immune activation that causes neurotoxicity, new technologies are being introduced, such as adjusting target affinity or controlling CAR activity temporarily with an 'On/Off switch'. The objective pediatric cognitive change data obtained in this clinical trial is expected to be used as an important benchmark when future next-generation CAR-T therapies obtain FDA or EMA approval. The company that secures a safe platform that overcomes long-term neurotoxicity will dominate the global immunotherapy market in the future.